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Effects of levomilnacipran extended-release on major
depressive disorder patients with cognitive impairments:
post-hoc analysis of a phase III study
Keith A. Wesnesa,b,c, Carl Gommolld, Changzheng Chend,
Angelo Sambunarise, Roger S. McIntyref and Philip D. Harveyg
Performance-based cognitive data were collected using the
Cognitive Drug Research System in a study of
levomilnacipran extended-release (ER) 40–120mg/day
(NCT01034462) in adults with major depressive disorder.
These data were analyzed post-hoc to explore the
relationship between cognitive measures, depression
symptoms (Montgomery–Åsberg Depression Rating Scale,
MADRS), and self-reported psychosocial functioning
(Sheehan Disability Scale; SDS). Changes from baseline
were analyzed in the intent-to-treat population and
subgroups with impaired attention, as indicated by baseline
Cognitive Drug Research System scores for Power of
Attention and Continuity of Attention. Path analyses
evaluated the direct and indirect effects of levomilnacipran
ER on SDS total score change. Significantly greater
improvements were observed for levomilnacipran ER
versus placebo for Power of Attention, Continuity of
Attention, MADRS, and SDS score changes; the mean
differences were larger in the impaired subgroups than in
the overall intent-to-treat population. Path analyses showed
that the majority of SDS total score improvement (≥50%)
was attributable to an indirect treatment effect through
MADRS total score change; some direct effect of
levomilnacipran ER on SDS total score improvement was
also observed. In adults with major depressive disorder,
levomilnacipran ER effectively improved measures of
depression and cognition, which contributed toward
reductions in self-reported functional impairment. Int Clin
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Introduction
The diagnostic criteria for major depressive disorder
(MDD) include cognitive symptoms such as diminished
ability to concentrate or think, indecisiveness, and psy-
chomotor retardation (American Psychiatric Association,
2013). The general prevalence of cognitive symptoms in
MDD is not known (Trivedi and Greer, 2014), but results
from a clinic-based study (Lam et al., 2012) and the
STAR*D trial (Hollon et al., 2006) indicate that ∼ 90% of
patients report difficulties with concentration, memory,
and/or decision making. Such impairments can negatively
affect psychosocial functioning and the ability to work
(Mcintyre et al., 2013; Evans et al., 2014). In a study of
gainfully employed adults with MDD, cognitive dys-
function accounted for impairment in workplace
productivity to an even greater extent than total
depression severity (Mcintyre et al., 2015).
Multiple studies have reported persistent impairments in
performance-based assessments of cognition after reso-
lution of depression symptoms, and in patients with
recurrent depressive episodes, cognitive impairments can
become more severe with each subsequent episode (Neu
et al., 2005; Baune and Renger, 2014; Trivedi and Greer,
2014; Papakostas, 2015; Maeshima et al., 2016). Such
persistence suggests that cognitive impairment may be
both a state marker and a trait marker of depression
(Baune and Renger, 2014), and that depression itself may
have a lasting impact on cognitive ability (Baune et al.,
2010). The problems of residual and worsening cognitive
symptoms highlight the importance of choosing medi-
cations that not only improve depression symptoms but
also the cognitive impairments associated with MDD.
Widely varying methods have been used to evaluate the
effects of antidepressants on cognition in patients with
MDD. Meta-analyses of these studies indicate limited
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evidence for some medications over placebo in certain
cognitive domains, such as the effects of duloxetine on
processing speed and verbal memory or reboxetine on
processing speed and continuity of attention (COA)
(Keefe et al., 2014; Rosenblat et al., 2015). The most
consistent effects have been found with vortioxetine
(Al-Sukhni et al., 2015), which include results from
double-blind, placebo-controlled studies in which objec-
tive tests of cognition were defined as the primary efficacy
parameter (Mcintyre et al., 2014; Mahableshwarkar et al.,
2015). Path analyses in these studies showed vortioxetine
to have direct treatment effects on cognition. In contrast
to these newer antidepressants, some of the older phar-
macotherapies, such as tricyclic antidepressants, can have
anticholinergic or sedative effects that may interfere with
cognitive function (Biringer et al., 2009).
Levomilnacipran extended-release (ER) is a serotonin
and norepinephrine reuptake inhibitor currently
approved in the USA for the treatment of MDD in adults
(Forest, 2014). In one of the pivotal phase III studies
(NCT01034462) that served as the basis for US approval
(Sambunaris et al., 2014), cognition was evaluated using
three computerized tests of attention from the Cognitive
Drug Research (CDR) System (Keith et al., 1998;
Ferguson et al., 2003; Vasudev et al., 2012). On the basis
of predefined statistical analyses for the CDR System
measures, the original trial report indicated a significantly
greater improvement with levomilnacipran ER versus
placebo on the Continuity of Attention (COA) score
(P= 0.0036) and a trend toward statistical significance on
the Power of Attention (POA) score (P= 0.0666). The
current report includes additional analyses that were
carried out to further investigate the effects of levo-
milnacipran ER on cognition and explore the relationship
between changes in cognitive measures, mood symp-
toms, and functional impairments in adult MDD patients
treated with levomilnacipran ER.
Methods
Study design and participants
Post-hoc analyses were carried out using data from an
8-week, randomized, double-blind, placebo-controlled,
flexible-dose study of levomilnacipran ER 40–120mg/day
in adults with a Diagnostic and Statistical Manual of Mental
Disorders, 4th ed., text revision (DSM-IV-TR) diagnosis of
MDD (Sambunaris et al., 2014). The study was carried out
in full compliance with Good Clinical Practice guidelines
and Declaration of Helsinki principles. All patients pro-
vided written informed consent before any study
procedures.
Details of eligibility and study design have been published
previously (Sambunaris et al., 2014). Key criteria for inclusion
were current depressive episode (duration≥4 weeks) and
clinician-rated Montgomery–Åsberg Depression Rating
Scale (MADRS) total score of 30 or more. Key exclusion
criteria were as follows: any axis I disorder other than MDD
within 6 months before screening; lifetime history of any
other major psychiatric diagnosis; substance abuse or
dependence within 6 months before screening; comorbid
anxiety-related or phobia-related disorder; history of non-
response to adequate treatment with two or more anti-
depressants; significant risk of suicide; and dementia,
amnesia, or other cognitive disorder. The primary and sec-
ondary efficacy outcomes were defined as changes from
baseline to week 8 in MADRS total score and Sheehan
Disability Scale (SDS) total score, respectively.
Cognitive assessments
The cognitive assessments in this study comprised three
CDR System tests of attention: digit vigilance, simple
reaction time, and choice reaction time. Four validated
composite scores (Wesnes et al., 2005) were derived from
these tests as follows: (a) POA, which is based on the
speed scores from all three tests and reflects the ability to
temporarily focus attention and efficiently process infor-
mation; (b) COA, which is based on measures of accuracy
from the choice reaction time and digit vigilance tests and
reflects the ability to sustain attention; (c) cognitive
reaction time, which is the additional response time
taken in the choice reaction time test over that from
simple reaction time test and reflects central processing
speed; and (d) reaction time variability, which is based on
the coefficients of variation of the speed scores in the
three tasks and reflects fluctuations in attention. Overall,
these four measures incorporate all nine of the outcome
measures from the three tasks. Self-ratings of mood and
alertness were also measured using the three-factor scores
from the Bond–Lader visual analog scales: alertness,
calmness, and contentment (Bond and Lader, 1974).
Changes from baseline to week 8 in the four CDR
System composite scores (POA, COA, cognitive reaction
time, reaction time variability) and the three self-rated
visual analog scale scores (alertness, calmness, content-
ment) were defined in the study as additional efficacy
parameters.
Post-hoc analyses
The median POA and COA scores at baseline in the
predefined intent-to-treat (ITT) population (i.e. all ran-
domized patients who received ≥ 1 dose of double-blind
study drug and had ≥ 1 postbaseline MADRS assess-
ment) were used to categorize patients with ‘higher’
cognitive impairment (POA score≥ 1303 or COA
score< 92) and ‘lower’ cognitive impairment (POA
score< 1303 or COA score≥ 92). Median scores were
selected as cutoffs to segregate the ITT population into
two sets of similarly sized subgroups with different levels
of cognitive impairment. These cutoffs are not intended
to provide any information on cognitive impairment of
the subgroups relative to healthy controls.
In the ITT population, changes from baseline to end of
treatment in CDR System and Bond–Lader scores were
2 International Clinical Psychopharmacology 2016, Vol 00 No 00
analyzed post hoc using an analysis of covariance model
that included treatment as a factor and baseline score as
a covariate with missing data handled using a last
observation carried forward approach. The same ana-
lyses were carried out in the POA and COA subgroups,
but with subgroup category (POA≥ 1303, COA< 92,
POA< 1303, COA≥ 92) and treatment-by-category
interactions added as factors. In contrast to the pre-
defined statistical analyses for these measures, the cur-
rent post-hoc analyses did not include site as a factor
since the tests were computerized and were not likely to
be dependent on administration by individual investi-
gators at different study sites. In addition, the data were
automatically recorded and analyzed, removing another
source of potential intersite variability.
Changes from baseline to week 8 in MADRS total, SDS
total, and SDS subscale scores were analyzed in the ITT
population using a mixed-effects model for repeated
measures with treatment, pooled study site, visit, and
treatment-by-visit interaction as factors, and baseline
score and baseline-by-visit interaction as covariates. The
same analyses were carried out in the POA and COA
subgroups, but with subgroup category, visit-by-
category, treatment-by-category, and visit-by-treat-
ment-by-category as factors. For the POA and COA
subgroup analyses, the treatment-by-category interac-
tion was tested for statistical significance at the 0.10
level of signficance. All other statistical tests were per-
formed at the 0.05 level of significance.
Two path analyses were constructed using data from
levomilnacipran ER-treated patients in the ITT popu-
lation. The first path analysis (model 1) evaluated the
direct effects of levomilnacipran ER on the change from
baseline in SDS total score, along with the indirect
effects through changes from baseline in MADRS total
score and POA score. The second path analysis (model
2) also evaluated the direct effects of levomilnacipran
ER on SDS total score change, but evaluated the
indirect effects through MADRS total and COA score
changes. All direct and indirect effects, derived from
regression coefficients, are presented as percentages
relative to the total levomilnacipran ER treatment effect
on outcome (i.e. direct effect plus indirect effects).
These percentages do not take into account any vari-
ables that were not included in the models or other
extraneous factors such as variance or measurement
errors. Standardized scoring [(observed change−mean
change)/SD] was implemented in all path analyses to
adjust for the use of assessment scales that had very
different possible score ranges.
Results
Patients
Baseline characteristics were generally similar between
treatment groups in the ITT population (Table 1).
However, the percentage of patients with recurrentTa
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episodes (i.e. had ≥ 1 previous major depressive episode
before the current episode) and the mean MDD duration
(i.e. time from first onset of mood symptoms) appeared to
differ between treatment groups within the higher and
lower cognitive impairment subgroups. The reason for
this imbalance is not obvious, but the other baseline
characteristics were generally similar between the levo-
milnacipran ER and placebo groups within each cogni-
tive impairment subgroup.
Effects of treatment on cognitive function
Significantly greater POA and COA score improvements
were found with levomilnacipran ER versus placebo in
the ITT population and in the higher cognitive impair-
ment subgroups (POA≥ 1303, COA< 92) (Fig. 1).
Although the least-squares mean differences (LSMDs)
for levomilnacipran ER versus placebo were greater in
the higher cognitive impairment subgroups than in the
lower cognitive impairment subgroups, no statistical dif-
ferences between subgroups (P> 0.10) were detected,
except for change in the COA score (POA≥ 1303 vs.
< 1303) (Fig. 1b).
Significantly greater mean improvements from baseline
with levomilnacipran ER versus placebo were also found
for reaction time variability in the ITT population and in
the higher cognitive impairment subgroups, as well as for
self-rated contentment in the POA≥ 1303 subgroup
(Table 2). No significant differences were found between
levomilnacipran ER and placebo for cognitive reaction
time, self-rated alertness, or self-rated contentment.
Effects of baseline cognitive impairment on treatment
outcomes
In the ITT population, treatment with levomilnacipran
ER versus placebo resulted in significantly greater mean
improvements from baseline in both the MADRS total
score (LSMD=− 3.10; P= 0.0051) and the SDS total
score (LSMD=− 2.63; P= 0.0010) (Fig. 2), as well as in
all three SDS subscale scores (Fig. 3).
Mean improvements in these outcome measures were
also significantly greater with levomilnacipran ER versus
placebo in the subgroups of patients with higher cogni-
tive impairment. Although the LSMDs for levomilnaci-
pran ER versus placebo in the higher cognitive
impairment subgroups (POA≥ 1303 and COA< 92 sub-
groups) were generally larger than those found in the
ITT population and the lower cognitive impairment
subgroups, the differences between the higher and the
lower cognitive impairment subgroups were not sig-
nificant (P> 0.10) for MADRS total, SDS total, and SDS
work/school subscale score changes from baseline (Figs 2
and 3). However, significant differences (P< 0.10) in
treatment effect (LSMDs for levomilnacipran ER vs.
placebo) were found between higher and lower cognitive
impairment groups for the SDS social life (POA≥ 1303
vs. < 1303; COA< 92 vs. ≥ 92) and SDS family/home life
(COA< 92 vs. ≥ 92) score changes from baseline (Fig. 3b
and c).
Path analyses
In model 1, the direct treatment effect of levomilnacipran
ER on SDS total score change was 11.1%; the indirect
effects through MADRS total score change and POA
score change were 80.9 and 8.0%, respectively. In model
2, the direct treatment effect of levomilnacipran ER on
SDS total score change was 48.4%; the indirect effects
through MADRS total score change and COA score
change were 51.2 and 0.3%, respectively.
Discussion
The availability of CDR System data from a phase III
trial of levomilnacipran ER in adults with MDD
(Sambunaris et al., 2014) provided an opportunity to
assess the effects of this medication on computer-based,
composite measures of attention and to explore the
relationship between changes in these cognitive mea-
sures and functional impairment. These post-hoc ana-
lyses indicate that relative to placebo, levomilnacipran
ER significantly improved three of the four CDR System
composite measures (POA, COA, reaction time varia-
bility) in the ITT population.
Cognitive declines were observed with placebo in the
higher cognitive impairment subgroups (POA≥ 1303 and
COA< 92). As indicated by POA and COA score changes
from baseline (Fig. 1), patients in the higher cognitive
impairment subgroups worsened with placebo, whereas
patients with lower impairment generally improved (or
showed less worsening) with placebo. Consequently,
larger treatment effects (i.e. LSMDs for levomilnacipran
ER vs. placebo) on POA and COA score changes were
observed in higher cognitive impairment subgroups.
However, the difference in the magnitude of treatment
effect between cognitive impairment subgroups was
statistically significant for only 1 of the 4 comparisons
(POA≥ 1303 vs. POA< 1303 for COA score change from
baseline). It is also worth noting that the placebo results
for POA score change (decline in higher cognitive
impairment subgroups, improvement in lower cognitive
impairment subgroups) rule out ‘regression to the mean’
as a possible explanation for the POA score improve-
ments that were observed with levomilnacipran ER in
patients with higher levels of cognitive impairment at
baseline (Fig. 1a).
Two validated measures, one rated by the investigator
and the other self-reported by the patient (MADRS and
SDS, respectively), were predefined in this trial as the
primary and secondary efficacy measures, respectively.
As reported previously for the ITT population
(Sambunaris et al., 2014) and presented again here (Figs 2
and 3), treatment with levomilnacipran ER versus pla-
cebo resulted in significantly greater improvements in
MADRS total, SDS total, and all three SDS subscale
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scores. Treatment effects (i.e. LSMDs for levomilnaci-
pran ER vs. placebo) were numerically larger in the
higher cognitive impairment subgroups relative to the
lower impairment subgroups, although the differences
between subgroups were only statistically significant for
two SDS subscales (social life, family/home life) (Fig. 3).
On the basis of the predefined efficacy analyses, it was
already known that levomilnacipran ER significantly
improved depression symptoms (MADRS total score)
and self-reported functional impairment (SDS total score)
relative to placebo in this trial (Sambunaris et al., 2014). It
was not known, however, the degree to which levo-
milnacipran ER might have directly affected the change
in the SDS total score relative to any indirect effects
through changes in MADRS total score and POA or COA
score. Two path analyses were carried out to explore this
question, both of which indicated a limited indirect effect
through POA score change (8.0%) or COA score change
(0.3%). These results were not entirely unexpected as
the SDS is a patient-reported measure, whereas POA and
COA are objective measures, and subjective measures of
functioning do not correlate as strongly with objective
measures of cognition as they do with subjective mea-
sures of cognition (Naismith et al., 2007). Future inves-
tigations of the effects of cognitive improvements on
functional impairment may need to take into considera-
tion the types of measures being used. For example, path
analyses that include objective measures of cognition,
such as the POA or COA, may be more informative if
they also include an objective measure of functioning,
such as the rating of functional disability by an informant
who knows the patient well (e.g. caregiver or high-
contact clinician). In contrast to self-reported measures
of functional impairment, this type of functional evalua-
tion has been found to correlate with cognitive perfor-
mance (Harvey and Keefe, 2015).
Results from the two path analyses differed in terms of
the direct treatment effect and the indirect treatment
effect through MADRS total score change. In model 1
(which included POA score change in addition to
MADRS total score change as factors for estimating
Fig. 1
Mean changes from baseline in POA (a) and COA (b) scores. Subgroups
were defined using the median POA and COA scores at baseline. For
interaction analyses, §significance at the 0.1 level. *P<0.05; **P<0.01;
***P<0.001 for levomilnacipran ER versus placebo for score changes.
COA, Continuity of Attention; ER, extended-release; ITT, intent-to-treat;
n, number of patients with available assessments at baseline and end of
treatment; LS, least squares; LSMD, least-squares mean difference
between treatment groups; ns, not significant; POA, Power of Attention.
Table 2 Effects of treatment on additional cognition measures
Lower cognitive impairment subgroupsa Higher cognitive impairment subgroupsa
ITT population POA<1303 COA≥92 POA≥1303 COA<92
CDR System composite scores [LSMD (95% CI)]
Cognitive reaction time 12.13 (−12.89–37.15) 5.02 (−30.49–40.53) −0.13 (−33.69–33.43) 17.37 (−18.16–52.90) 29.36 (−8.44–67.16)
Reaction time variability −0.01 (−0.02 to −0.00)b 0.00 (−0.01–0.02) −0.01 (−0.02–0.01) −0.03 (−0.04 to −0.01)b −0.02 (−0.04 to −0.01)b
Self-rated Bond–Lader scores [LSMD (95% CI)]
Alertness 3.17 (−0.25–6.59) 2.09 (−2.81–6.98) 2.23 (−2.39–6.86) 4.29 (−0.53–9.11) 4.58 (−0.53–9.69)
Calmness 0.42 (−2.66–3.50) 0.43 (−3.98–4.85) −1.15 (−5.32–3.02) 0.35 (−3.99–4.69) 2.45 (−2.16–7.05)
Contentment 3.68 (−0.31–7.67) 1.61 (−4.08–7.30) 2.77 (−2.62–8.15) 5.76 (0.16–11.36)b 5.38 (−0.57–11.32)
CDR, Cognitive Drug Research; CI, confidence interval; COA, continuity of attention; ER, extended-release; ITT, intent-to-treat; LSMD, least-squares mean difference
between treatment groups in the mean score change from baseline; POA, Power of Attention.
aSubgroups were defined using the median POA and COA scores at baseline.
bP<0.05, levomilnacipran ER versus placebo.
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indirect treatment effects), the effect of levomilnacipran
ER on SDS total score was mostly indirect through
MADRS total score change (80.9%). However, in model
2 (which included COA score change and MADRS total
score change as factors), the indirect effect of levo-
milnacipran ER on SDS total score change through
MADRS total score change (51.2%) was roughly equal to
the direct treatment effect (48.4%). It is difficult to
ascertain why one model had a negligible direct treat-
ment effect whereas the other had ∼50% direct treatment
effect, although it is important to note that path analysis
Fig. 2
Mean changes from baseline in MADRS (a) and SDS (b) total scores.
Subgroups were defined using the median POA and COA scores at
baseline. *P<0.05; **P<0.01; ***P=0.001 for levomilnacipran ER
versus placebo for score changes. COA, Continuity of Attention; ER,
extended-release; ITT, intent-to-treat; LS, least squares; LSMD, least-
squares mean difference between treatment groups; MADRS,
Montgomery–Åsberg Depression Rating Scale; n, number of patients
with available assessments at baseline and end of treatment; ns, not
significant; POA, Power of Attention; SDS, Sheehan Disability Scale.
Fig. 3
Mean changes from baseline in SDS subscale (a–c) scores. Subgroups
were defined using the median POA and COA scores at baseline. For
interaction analyses, §significance at the 0.1 level. *P<0.05; **P<0.01;
***P<0.001 for levomilnacipran ER versus placebo. COA, Continuity of
Attention; ER, extended-release; ITT, intent-to-treat; LSM, least-squares
mean; LSMD, least-squares mean difference between treatment
groups; n, number of patients with available assessments at baseline
and end of treatment; ns, not significant; POA, Power of Attention;
SDS, Sheehan Disability Scale.
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results vary depending on the factors that are included in
the model. Therefore, the path analyses in this report do
not account for any factors (e.g. mental or physical fati-
gue, reduced motivation) that may have also contributed
toward the effects of levomilnacipran ER on functional
impairment. What both path analyses do suggest, how-
ever, is that improvement in the MADRS total score
accounted for much (but probably not all) of the SDS
total score improvement, which is consistent with
numerous studies that have found the severity of
depression to be associated with self-reported functional
impairment in patients with MDD (Lam et al., 2011).
What model 2 suggests is that some degree of functional
improvement may have been attributable to a direct
treatment effect with levomilnacipran ER.
More work is needed to better understand how
improvements in depression symptoms, cognitive dys-
function, and functional impairment are interrelated.
However, as it is already known that cognitive deficits
can persist during periods of remission and that residual
cognitive dysfunction can negatively impact occupational
functioning (Fava, 2003; Woo et al., 2016), the first step is
to establish whether an antidepressant can improve cog-
nitive impairments in addition to reducing the core
symptoms of depression. Whether such cognitive
improvements directly or indirectly contribute toward
diminished functional impairment and whether these
effects are pseudospecific are also important questions
that need to be examined concurrently with the clinical
task of finding medications that can effectively treat
cognitive impairments in patients with MDD who show
such symptoms.
Limitations
Although CDR System score changes were predefined in
the clinical trial as additional efficacy measures, the
cognitive impairment subgroup definitions and the sub-
sequent subgroup analyses were carried out post hoc. As
such, some baseline characteristics (e.g. MDD duration
and recurrent episodes) were not evenly distributed
between treatment groups in cognitive impairment sub-
groups, which may have had some effect on the out-
comes. Another potential limitation of these post-hoc
analyses was that the study was not designed to provide
sufficient statistical power in every subgroup, although
differences between levomilnacipran ER and placebo
were detected in many of the tested outcomes. Finally,
the analyses presented in this report focused on POA and
COA scores, which are primarily related to task-based
attention. Therefore, no conclusions can be drawn on the
effects of levomilnacipran ER on other types of cognitive
impairment (e.g. memory, learning, executive function-
ing) or the relationship of such measures with overall
psychosocial functioning. Moreover, as discussed earlier,
future studies may need to include performance-based
measures of everyday functional skills.
Conclusion
In addition to significantly greater improvements in
depression symptoms (MADRS total score) and func-
tional impairment (SDS total score), significantly greater
improvements in two objective measures of attention
were found with levomilnacipran ER versus placebo in
adult MDD patients. Path analyses indicated that
improvements in functional impairment during treatment
with levomilnacipran ER were partly because of the
direct effects of levomilnacipran ER and partly because
of the improvements in MDD symptoms associated with
levomilnacipran ER treatment.
Acknowledgements
The authors thank Jeff Lai from Allergan (Irvine,
California, USA) for carrying out the path analyses and for
his assistance in interpreting the results. Writing and
editorial support was provided by Mildred Bahn of
Prescott Medical Communications Group (Chicago,
Illinois, USA), a contractor of Allergan Inc.
The study and analyses presented in this report were
funded by the Forest Research Institute Inc., an Allergan
affiliate.
Conflicts of interest
At the time of the study, Keith Wesnes was an employee
and stockholder in Bracket Inc., the company that supplied
the CDR System for the study. Since February 2014, he
has run his own company, Wesnes Cognition Ltd, which
provides consultancy for Bracket as well as for pharma-
ceutical and nutraceutical companies. Angelo Sambunaris
is an employee of the Institute for Advanced Medical
Research and has received clinical research grant support
from the Forest Research Institute (an Allergan affiliate),
Alkermes, Cerecor, Daiichi-Sankyo, Indivior, Lundbeck,
Merck, Otsuka, Palatin, Pfizer, and Tal Medical, as well as
from Duke University School of Medicine. Roger S.
McIntyre has received research grant support from
Lundbeck, AstraZeneca, Pfizer, Shire, Otsuka, Bristol-
Myers Squibb, National Institute of Mental Health,
Stanley Medical Research Institute, Canadian Institutes for
Health Research, and The Brain and Behavior Research
Foundation. He has also received speaker/consultant fees
from Lundbeck, Pfizer, AstraZeneca, Eli Lilly, Janssen
Ortho, Sunovion, Takeda, Forest, Otsuka, Bristol-Myers
Squibb, and Shire. Philip D. Harvey has been a consultant
for Boehringer Ingelheim, Forest Laboratories (an Allergan
affiliate), FORUM Pharmaceuticals, Genentech,
Lundbeck, Otsuka, Hoffman-La Roche, Sanofi, Sunovion
Pharmaceuticals, and Takeda Pharmaceutical Company.
Carl Gommoll and Changzheng Chen are full-time
employees of Allergan.
References
Al-Sukhni M, Maruschak NA, Mcintyre RS (2015). Vortioxetine: a review of effi-
cacy, safety and tolerability with a focus on cognitive symptoms in major
depressive disorder. Expert Opin Drug Saf 14:1291–1304.
Levomilnacipran ER effects on cognition Wesnes et al. 7
American Psychiatric Association (2013). Diagnostic and statistical manual of
mental disorders: DSM-5. Washington, DC: American Psychiatric
Association.
Baune BT, Renger L (2014). Pharmacological and non-pharmacological inter-
ventions to improve cognitive dysfunction and functional ability in clinical
depression–a systematic review. Psychiatry Res 219:25–50.
Baune BT, Miller R, Mcafoose J, Johnson M, Quirk F, Mitchell D (2010). The role of
cognitive impairment in general functioning in major depression. Psychiatry
Res 176:183–189.
Biringer A, Rongve A, Lund A (2009). A review of modern antidepressants’ effects
on neurocogntive function. Curr Psychiatry Rev 5:164–174.
Bond L, Lader M (1974). The use of analogue scales in rating subjective feelings.
Br J Med Psychol 47:211–218.
Evans VC, Iverson GL, Yatham LN, Lam RW (2014). The relationship between
neurocognitive and psychosocial functioning in major depressive disorder: a
systematic review. J Clin Psychiatry 75:1359–1370.
Fava M (2003). Symptoms of fatigue and cognitive/executive dysfunction in major
depressive disorder before and after antidepressant treatment. J Clin
Psychiatry 64 (Suppl 14):30–34.
Ferguson JM, Wesnes KA, Schwartz GE (2003). Reboxetine versus paroxetine
versus placebo: effects on cognitive functioning in depressed patients. Int
Clin Psychopharmacol 18:9–14.
Forest (2014). Fetzima (levomilnacipran) extended release Prescribing informa-
tion. New York, NY: Forest Laboratories Inc.
Harvey PD, Keefe RS (2015). Methods for delivering and evaluating the efficacy of
cognitive enhancement. Handb Exp Pharmacol 228:5–25.
Hollon SD, Shelton RC, Wisniewski S, Warden D, Biggs MM, Friedman ES, et al.
(2006). Presenting characteristics of depressed outpatients as a function of
recurrence: preliminary findings from the STAR*D clinical trial. J Psychiatr Res
40:59–69.
Keefe RS, Mcclintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M (2014).
Cognitive effects of pharmacotherapy for major depressive disorder: a
systematic review. J Clin Psychiatry 75:864–876.
Keith MS, Stanislav SW, Wesnes KA (1998). Validity of a cognitive computerized
assessment system in brain-injured patients. Brain Inj 12:1037–1043.
Lam RW, Filteau MJ, Milev R (2011). Clinical effectiveness: the importance of
psychosocial functioning outcomes. J Affect Disord 132 (Suppl 1):S9–S13.
Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN (2012). Which
depressive symptoms and medication side effects are perceived by patients
as interfering most with occupational functioning? Depress Res Treat
2012:630206.
Maeshima H, Baba H, Satomura E, Shimano T, Inoue M, Ishijima S, et al. (2016).
Residual memory impairment in remitted depression may be a predictive
factor for recurrence. J Clin Psychiatry 77:247–251.
Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS (2015). A
randomized, placebo-controlled, active-reference, double-blind, flexible-dose
study of the efficacy of vortioxetine on cognitive function in major depressive
disorder. Neuropsychopharmacology 40:2025–2037.
Mcintyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA,
Kudlow P, et al. (2013). Cognitive deficits and functional outcomes in major
depressive disorder: determinants, substrates, and treatment interventions.
Depress Anxiety 30:515–527.
Mcintyre RS, Lophaven S, Olsen CK (2014). A randomized, double-blind,
placebo-controlled study of vortioxetine on cognitive function in
depressed adults. Int J Neuropsychopharmacol 17:1557–1567.
Mcintyre RS, Soczynska JZ, Woldeyohannes HO, Alsuwaidan MT, Cha DS,
Carvalho AF, et al. (2015). The impact of cognitive impairment on perceived
workforce performance: results from the International Mood Disorders
Collaborative Project. Compr Psychiatry 56:279–282.
Naismith SL, Longley WA, Scott EM, Hickie IB (2007). Disability in major
depression related to self-rated and objectively-measured cognitive deficits: a
preliminary study. BMC Psychiatry 7:32.
Neu P, Bajbouj M, Schilling A, Godemann F, Berman RM, Schlattmann P (2005).
Cognitive function over the treatment course of depression in middle-aged
patients: correlation with brain MRI signal hyperintensities. J Psychiatr Res
39:129–135.
Papakostas GI (2015). Antidepressants and their effect on cognition in major
depressive disorder. J Clin Psychiatry 76:e1046.
Rosenblat JD, Kakar R, Mcintyre RS (2015). The cognitive effects of anti-
depressants in major depressive disorder: a systematic review and meta-
analysis of randomized clinical trials. Int J Neuropsychopharmacol 19:
doi:10.1093/ijnp/pyv082.
Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV
(2014). A phase III, double-blind, placebo-controlled, flexible-dose study of
levomilnacipran extended-release in patients with major depressive disorder.
J Clin Psychopharmacol 34:47–56.
Trivedi MH, Greer TL (2014). Cognitive dysfunction in unipolar depression:
implications for treatment. J Affect Disord 152–154:19–27.
Vasudev A, Saxby BK, O’brien JT, Colloby SJ, Firbank MJ, Brooker H, et al. (2012).
Relationship between cognition, magnetic resonance white matter hyper-
intensities, and cardiovascular autonomic changes in late-life depression. Am
J Geriatr Psychiatry 20:691–699.
Wesnes KA, Mckeith I, Edgar C, Emre M, Lane R (2005). Benefits of rivastigmine
on attention in dementia associated with Parkinson disease. Neurology
65:1654–1656.
Woo YS, Rosenblat JD, Kakar R, Bahk WM, Mcintyre RS (2016). Cognitive
deficits as a mediator of poor occupational function in remitted major
depressive disorder patients. Clin Psychopharmacol Neurosci 14:1–16.
8 International Clinical Psychopharmacology 2016, Vol 00 No 00
